OWP
TRDA icon

Old Well Partners’s Entrada Therapeutics TRDA Stock Holding History

Old Well Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,700
Closed -$155K – 43
2022
Q2 		$155K Buy
+12,700
New +$96.3K 0.12% 28

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Old Well Partners's TRDA Position: Q3 2022 in Review

Old Well Partners sold out of Entrada Therapeutics (TRDA) in Q3 2022, closing a stake of 12,700 shares — an estimated $155K sold.

Old Well Partners first reported a position in TRDA in Q2 2022 and held it in 1 quarter. The position peaked at $155K in Q2 2022. 33 funds tracked by Wall St. Rank hold TRDA as of Q3 2022.

  • Old Well Partners reported no remaining Entrada Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Old Well Partners sold 12,700 Entrada Therapeutics shares in Q3 2022, an estimated $155K.
  • Old Well Partners first reported a position in Entrada Therapeutics in Q2 2022 and held it in 1 quarter.
  • Old Well Partners's Entrada Therapeutics position peaked at $155K in Q2 2022.
  • 33 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2022.

Based on Old Well Partners's 13F filing for Q3 2022, filed 14 Nov 2022.